JP2003509028A - 核移植技術を用いた免疫適合性を有する細胞及び組織を産生する方法 - Google Patents
核移植技術を用いた免疫適合性を有する細胞及び組織を産生する方法Info
- Publication number
- JP2003509028A JP2003509028A JP2001522404A JP2001522404A JP2003509028A JP 2003509028 A JP2003509028 A JP 2003509028A JP 2001522404 A JP2001522404 A JP 2001522404A JP 2001522404 A JP2001522404 A JP 2001522404A JP 2003509028 A JP2003509028 A JP 2003509028A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- tissue
- animal
- cell
- teratoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012546 transfer Methods 0.000 title claims abstract description 39
- 238000005516 engineering process Methods 0.000 title description 4
- 238000004519 manufacturing process Methods 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 89
- 238000002054 transplantation Methods 0.000 claims abstract description 53
- 210000004027 cell Anatomy 0.000 claims description 223
- 210000001519 tissue Anatomy 0.000 claims description 133
- 241001465754 Metazoa Species 0.000 claims description 68
- 206010043276 Teratoma Diseases 0.000 claims description 59
- 230000002438 mitochondrial effect Effects 0.000 claims description 53
- 108020005196 Mitochondrial DNA Proteins 0.000 claims description 49
- 108090000623 proteins and genes Proteins 0.000 claims description 39
- 239000000427 antigen Substances 0.000 claims description 35
- 108091007433 antigens Proteins 0.000 claims description 35
- 102000036639 antigens Human genes 0.000 claims description 35
- 210000000130 stem cell Anatomy 0.000 claims description 29
- 210000001161 mammalian embryo Anatomy 0.000 claims description 28
- 230000000735 allogeneic effect Effects 0.000 claims description 27
- 241000283690 Bos taurus Species 0.000 claims description 21
- 241000124008 Mammalia Species 0.000 claims description 21
- 238000012360 testing method Methods 0.000 claims description 18
- 210000000287 oocyte Anatomy 0.000 claims description 16
- 230000001225 therapeutic effect Effects 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 210000002027 skeletal muscle Anatomy 0.000 claims description 14
- 108091093105 Nuclear DNA Proteins 0.000 claims description 13
- 210000003491 skin Anatomy 0.000 claims description 12
- 210000001654 germ layer Anatomy 0.000 claims description 11
- 210000004698 lymphocyte Anatomy 0.000 claims description 11
- 238000010171 animal model Methods 0.000 claims description 10
- 230000028993 immune response Effects 0.000 claims description 10
- 241000894007 species Species 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 210000003370 receptor cell Anatomy 0.000 claims description 9
- 206010061598 Immunodeficiency Diseases 0.000 claims description 8
- 210000002950 fibroblast Anatomy 0.000 claims description 8
- 210000003734 kidney Anatomy 0.000 claims description 8
- 210000005084 renal tissue Anatomy 0.000 claims description 8
- 210000002460 smooth muscle Anatomy 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 210000004165 myocardium Anatomy 0.000 claims description 7
- 230000024245 cell differentiation Effects 0.000 claims description 6
- 210000003195 fascia Anatomy 0.000 claims description 6
- 238000003306 harvesting Methods 0.000 claims description 6
- 239000007943 implant Substances 0.000 claims description 6
- 210000000944 nerve tissue Anatomy 0.000 claims description 6
- 210000003754 fetus Anatomy 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 239000005090 green fluorescent protein Substances 0.000 claims description 4
- 210000000987 immune system Anatomy 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 238000011580 nude mouse model Methods 0.000 claims description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 2
- 108060001084 Luciferase Proteins 0.000 claims description 2
- 239000005089 Luciferase Substances 0.000 claims description 2
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 2
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 2
- 210000001082 somatic cell Anatomy 0.000 claims description 2
- 238000010998 test method Methods 0.000 claims description 2
- 230000004077 genetic alteration Effects 0.000 claims 2
- 231100000118 genetic alteration Toxicity 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 1
- 108700019146 Transgenes Proteins 0.000 abstract description 3
- 238000012411 cloning technique Methods 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- 210000004940 nucleus Anatomy 0.000 description 22
- 210000003470 mitochondria Anatomy 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 230000035772 mutation Effects 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 15
- 238000010367 cloning Methods 0.000 description 14
- 210000000056 organ Anatomy 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 12
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 11
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 206010052779 Transplant rejections Diseases 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 241000283707 Capra Species 0.000 description 7
- 241001494479 Pecora Species 0.000 description 7
- 210000000845 cartilage Anatomy 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 230000002107 myocardial effect Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 108700008625 Reporter Genes Proteins 0.000 description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 4
- 108091054437 MHC class I family Proteins 0.000 description 4
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 4
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 210000004413 cardiac myocyte Anatomy 0.000 description 4
- 230000011712 cell development Effects 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000013020 embryo development Effects 0.000 description 4
- 210000001671 embryonic stem cell Anatomy 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000001744 histochemical effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 101100264174 Mus musculus Xiap gene Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102000012751 Pyruvate Dehydrogenase Complex Human genes 0.000 description 3
- 108010090051 Pyruvate Dehydrogenase Complex Proteins 0.000 description 3
- 238000011579 SCID mouse model Methods 0.000 description 3
- 102000005937 Tropomyosin Human genes 0.000 description 3
- 108010030743 Tropomyosin Proteins 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000001612 chondrocyte Anatomy 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000001900 endoderm Anatomy 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000003365 immunocytochemistry Methods 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000003716 mesoderm Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 230000009772 tissue formation Effects 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- QCHQVPPBLFSODM-MZWCVTMLSA-N Ac-Asp-Lys-Ala-Thr-Ile-Gly-Phe-Glu-Val-Gln-Glu-Glu Chemical compound OC(=O)C[C@H](NC(C)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CC1=CC=CC=C1 QCHQVPPBLFSODM-MZWCVTMLSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 206010068051 Chimerism Diseases 0.000 description 2
- 102100030878 Cytochrome c oxidase subunit 1 Human genes 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 102100027152 Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial Human genes 0.000 description 2
- 101710205862 Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108700005089 MHC Class I Genes Proteins 0.000 description 2
- 206010051403 Mitochondrial DNA deletion Diseases 0.000 description 2
- 208000030768 Optic nerve injury Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 102000013394 Troponin I Human genes 0.000 description 2
- 108010065729 Troponin I Proteins 0.000 description 2
- 239000000370 acceptor Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000003367 anti-collagen effect Effects 0.000 description 2
- 230000002529 anti-mitochondrial effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 210000003981 ectoderm Anatomy 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000003716 rejuvenation Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 2
- 210000002363 skeletal muscle cell Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 108010030844 2-methylcitrate synthase Proteins 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 101100325793 Arabidopsis thaliana BCA2 gene Proteins 0.000 description 1
- 206010004659 Biliary cirrhosis Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 101150087323 COI gene Proteins 0.000 description 1
- 240000002317 Camassia leichtlinii Species 0.000 description 1
- 235000000459 Camassia leichtlinii Nutrition 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010071536 Citrate (Si)-synthase Proteins 0.000 description 1
- 102000006732 Citrate synthase Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- 102000009093 Dihydrolipoyllysine-residue acetyltransferase Human genes 0.000 description 1
- 108010073112 Dihydrolipoyllysine-residue acetyltransferase Proteins 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 108050002220 Green fluorescent protein, GFP Proteins 0.000 description 1
- 102100036738 Guanine nucleotide-binding protein subunit alpha-11 Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000000435 Heart Rupture Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000027761 Hepatic autoimmune disease Diseases 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 101100283445 Homo sapiens GNA11 gene Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020961 Hypocholesterolaemia Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- -1 Imoran Chemical compound 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 101150118256 M3 gene Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108010086428 NADH Dehydrogenase Proteins 0.000 description 1
- 102000006746 NADH Dehydrogenase Human genes 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102100040557 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical group CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 208000031268 Rare optic nerve disease Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003409 anti-rejection Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 210000001172 blastoderm Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- GMTYREVWZXJPLF-AFHUBHILSA-N butorphanol D-tartrate Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O.N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 GMTYREVWZXJPLF-AFHUBHILSA-N 0.000 description 1
- 229960001590 butorphanol tartrate Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 210000001771 cumulus cell Anatomy 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000001162 elastic cartilage Anatomy 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229960000469 flunixin meglumine Drugs 0.000 description 1
- MGCCHNLNRBULBU-WZTVWXICSA-N flunixin meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O MGCCHNLNRBULBU-WZTVWXICSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003077 lignite Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005486 microgravity Effects 0.000 description 1
- 230000006676 mitochondrial damage Effects 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920005594 polymer fiber Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/04—Cells produced using nuclear transfer
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15235499P | 1999-09-07 | 1999-09-07 | |
| US60/152,354 | 1999-09-07 | ||
| US15510799P | 1999-09-22 | 1999-09-22 | |
| US60/155,107 | 1999-09-22 | ||
| PCT/US2000/024398 WO2001018193A1 (en) | 1999-09-07 | 2000-09-06 | Method for generating immune-compatible cells and tissues using nuclear transfer techniques |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003509028A true JP2003509028A (ja) | 2003-03-11 |
| JP2003509028A5 JP2003509028A5 (zh) | 2007-11-08 |
Family
ID=26849488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001522404A Pending JP2003509028A (ja) | 1999-09-07 | 2000-09-06 | 核移植技術を用いた免疫適合性を有する細胞及び組織を産生する方法 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1214403A4 (zh) |
| JP (1) | JP2003509028A (zh) |
| CN (1) | CN1376196A (zh) |
| AU (2) | AU783162B2 (zh) |
| BR (1) | BR0011905A (zh) |
| CA (1) | CA2383776A1 (zh) |
| IL (1) | IL148418A0 (zh) |
| MX (1) | MXPA02002444A (zh) |
| NZ (1) | NZ536786A (zh) |
| WO (1) | WO2001018193A1 (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003508079A (ja) * | 1999-09-07 | 2003-03-04 | アドバンスド セル テクノロジー、インコーポレイテッド | 老年期体細胞からクローン化された動物中の細胞寿命のテロメア回復と延長 |
| JP2012120486A (ja) * | 2010-12-08 | 2012-06-28 | Kinki Univ | 免疫不全動物を用いた細胞の製法 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6525242B1 (en) | 1999-11-02 | 2003-02-25 | The University Of Connecticut | Propagation of human hepatocytes in non-human mammals |
| WO2001059076A2 (en) * | 2000-02-09 | 2001-08-16 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Premeiotic and postmeiotic origin of teratomas: isolated teratoma stem cells for therapeutic uses |
| AU2003233679A1 (en) * | 2002-05-23 | 2003-12-12 | Advanced Cell Technology, Inc. | Generation of histocompatible tissues using nuclear transplantation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5453366A (en) * | 1990-07-26 | 1995-09-26 | Sims; Michele M. | Method of cloning bovine embryos |
| US5523226A (en) * | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| EP0934403A4 (en) * | 1996-08-19 | 2001-03-14 | Univ Massachusetts | ROWS OF EMBRYONIC OR STRAIN-LIKE CELLS PRODUCED BY CROSS NUCLEAR TRANSPLANTATION OF SPECIES |
| GB9809178D0 (en) * | 1998-04-29 | 1998-07-01 | Univ Edinburgh | Nuclear reprogramming of somatic cells |
| CA2334953A1 (en) * | 1999-06-30 | 2001-01-04 | Woo-Suk Hwang | Method for producing human cloned embryos by employing inter-species nuclear transplantation technique |
| NZ531844A (en) * | 1999-09-07 | 2005-08-26 | Advanced Cell Tech Inc | Telomere restoration and extension of cell life-span in animals cloned from senescent somatic cells |
| MXPA02002744A (es) * | 1999-09-14 | 2003-07-21 | Univ Massachusetts | Lineas de celulas embrionarias o tipo celulas madre y metodos para mejorar el desarrollo embrionario. |
| CN1413250A (zh) * | 1999-10-15 | 2003-04-23 | 先进细胞技术公司 | 用于生成分化祖细胞和谱系缺陷型胚胎干细胞的方法 |
-
2000
- 2000-09-06 WO PCT/US2000/024398 patent/WO2001018193A1/en active IP Right Grant
- 2000-09-06 JP JP2001522404A patent/JP2003509028A/ja active Pending
- 2000-09-06 MX MXPA02002444A patent/MXPA02002444A/es active IP Right Grant
- 2000-09-06 NZ NZ536786A patent/NZ536786A/en not_active IP Right Cessation
- 2000-09-06 CA CA002383776A patent/CA2383776A1/en not_active Abandoned
- 2000-09-06 BR BR0011905-9A patent/BR0011905A/pt not_active Application Discontinuation
- 2000-09-06 CN CN00813394A patent/CN1376196A/zh active Pending
- 2000-09-06 EP EP00964946A patent/EP1214403A4/en not_active Withdrawn
- 2000-09-06 AU AU75755/00A patent/AU783162B2/en not_active Expired
- 2000-09-06 IL IL14841800A patent/IL148418A0/xx unknown
-
2008
- 2008-12-22 AU AU2008261167A patent/AU2008261167A1/en not_active Ceased
Non-Patent Citations (1)
| Title |
|---|
| JPN7010002384, Ｒｅｐｒｏｄ Ｆｅｒｔｉｌ Ｄｅｖ．（１９９８ Ｊａｎ），Ｖｏｌ．１０，Ｎｏ．１，ｐ．１２１−１２５ * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003508079A (ja) * | 1999-09-07 | 2003-03-04 | アドバンスド セル テクノロジー、インコーポレイテッド | 老年期体細胞からクローン化された動物中の細胞寿命のテロメア回復と延長 |
| JP2012120486A (ja) * | 2010-12-08 | 2012-06-28 | Kinki Univ | 免疫不全動物を用いた細胞の製法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1214403A4 (en) | 2005-03-09 |
| WO2001018193A1 (en) | 2001-03-15 |
| AU2008261167A1 (en) | 2009-01-15 |
| BR0011905A (pt) | 2003-07-08 |
| MXPA02002444A (es) | 2004-07-16 |
| IL148418A0 (en) | 2002-09-12 |
| AU7575500A (en) | 2001-04-10 |
| NZ536786A (en) | 2006-09-29 |
| CN1376196A (zh) | 2002-10-23 |
| EP1214403A1 (en) | 2002-06-19 |
| CA2383776A1 (en) | 2001-03-15 |
| AU783162B2 (en) | 2005-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11234418B2 (en) | Genetically modified cells, tissues, and organs for treating disease | |
| CN109640645B (zh) | 用于治疗疾病的遗传修饰的细胞、组织和器官 | |
| US20120246746A1 (en) | Method for Generating Immune-Compatible Cells and Tissues Using Nuclear Transfer Techniques | |
| US20080003560A1 (en) | Tailor-made pluripotent stem cell and use of the same | |
| JP4814226B2 (ja) | 移植用臓器の調製方法 | |
| CN108697067A (zh) | 嵌合胚胎-辅助的器官制备的组合物和方法 | |
| Sackett et al. | Modulation of human allogeneic and syngeneic pluripotent stem cells and immunological implications for transplantation | |
| US6808704B1 (en) | Method for generating immune-compatible cells and tissues using nuclear transfer techniques | |
| AU2008261167A1 (en) | Method for generating immune-compatible cells and tissues using nuclear transfer techniques | |
| Steele et al. | Stem-like cells traffic from heart ex vivo, expand in vitro, and can be transplanted in vivo | |
| AU2005246949A1 (en) | Method for generating immune-compatible cells and tissues using nuclear transfer techniques | |
| De Lazaro Del Rey | In vivo cell reprogramming to pluripotency: generating induced pluripotent stem cells in situ for tissue regeneration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070905 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070905 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100803 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101102 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101110 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101126 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101203 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101228 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110111 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110401 |